Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

BACKGROUND. The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. An ancillary study was conducted to evaluate the circulating tumor cell (CTC) c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sastre, Javier, Maestro, M. Luisa, Gómez-España, Auxiliadora, Rivera, Fernando, Valladares, Manuel, Massuti, Bartomeu, Benavides, Manuel, Gallén, Manuel, Marcuello, Eugenio, Abad, Albert, Arrivi, Antonio, Fernández-Martos, Carlos, González, Encarnación, Tabernero, Josep M., Vidaurreta, Marta, Aranda, Enrique, Díaz-Rubio, Eduardo
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399651/
https://ncbi.nlm.nih.gov/pubmed/22643538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0048
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados